Clinical Trials
3 trialsNCT06405230 2026-02-03
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 1/2 Recruiting
NCT06879717 2026-01-16
PULMO-01
iOnctura
Phase 1/2 Active not recruiting
NCT05060432 2024-06-21
TIG-006
iTeos Therapeutics
Phase 1/2 Active not recruiting